We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
VIMPAT (UCB Australia Pty Ltd T/A UCB Pharma Division of UCB Australia)
Product name
VIMPAT
Date registered
Evaluation commenced
Decision date
Approval time
196 (255 working days)
Active ingredients
lacosamide
Registration type
EOI
Indication
VIMPAT (solution for inejction, oral solution, tablet) is now also indicated as add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older